Consolidation Therapy

Phase 3Small molecule

IInstitute of Hematology & Blood Diseases Hospital, China

Consolidation Therapy is one of 51 small molecule programs targeting Locally Advanced Rectal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Rectal AdenocarcinomaRecruiting

Acute Lymphoblastic Leukemia, AdultRecruiting

ChemotherapyNot yet recruiting

Locally Advanced Rectal AdenocarcinomaPhase 1

Recruiting

Acute Lymphoblastic Leukemia, AdultPreclinical

Recruiting

ChemotherapyPhase 3

Not yet recruiting

Competition

Competitive Landscape

116 competitors in Chemotherapy

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

20 2

Eloxatin

Teva

Phase 3

14 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

31 4

Avastin

Roche

Phase 3

12 5

Cytosar

Teva

Phase 3

11 6

Camptosar

Pfizer

Phase 3

8 7

Imfinzi

AstraZeneca

Phase 3

8 8

Vepesid

AAvyxa

Phase 3

23 9

Opdivo

Bristol-Myers Squibb

Phase 3

7 10

Beyfortus

BeiGene

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Recruiting

Locally Advanced Rectal Adenocarcinoma

NCT06834126

Q1 2030

PreclinicalRecruiting

Acute Lymphoblastic Leukemia, Adult

NCT07495631

Q4 2030

Phase 3Not yet recruiting

Chemotherapy

NCT07407140

Clinical

Trials by Indication[1]

Chemotherapy1 trial

VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 3·NCT07407140·300 enrolled

Acute Lymphoblastic Leukemia, Adult1 trial

A Prospective Cohort Study of a Pediatric-Inspired Chemotherapy Regimen Combined With Venetoclax and Immunotherapy for the Treatment of Adult Ph-Negative Acute Lymphoblastic Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT07495631·43 enrolled

Locally Advanced Rectal Adenocarcinoma1 trial

DINOMITE (Decreasing Hypoxia With Mitochondrial Inhibition in Locally Advanced Rectal Cancer): Phase 1 Trial of Papaverine in Combination With Radiation

Recruiting·CCity of Hope Medical Center·Phase 1·NCT06834126·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Consolidation Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Consolidation Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Consolidation Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

Consolidation Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2030

Q4 2030

Trials by Indication[1]

Chemotherapy1 trial

Acute Lymphoblastic Leukemia, Adult1 trial

Locally Advanced Rectal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News